RS57216B1 - Hemijske vrste - Google Patents

Hemijske vrste

Info

Publication number
RS57216B1
RS57216B1 RS20180576A RSP20180576A RS57216B1 RS 57216 B1 RS57216 B1 RS 57216B1 RS 20180576 A RS20180576 A RS 20180576A RS P20180576 A RSP20180576 A RS P20180576A RS 57216 B1 RS57216 B1 RS 57216B1
Authority
RS
Serbia
Prior art keywords
chemical entities
entities
chemical
Prior art date
Application number
RS20180576A
Other languages
English (en)
Inventor
Fernández Joaquín Pastor
Ruiz Oscar Fernández-Capetillo
González Sonia Martínez
Aparicio Carmen Blanco
Ferreira María Del Rosario Rico
Lázaro Luis Ignacio Toledo
Arísteguí Sonsoles Rodríguez
Costa Matilde Murga
Busto Carmen Varela
Contreras Andrés Joaquín Lopez
Oliver Renner
Soler María Nieto
Muñoz David Alvaro Cebrián
Original Assignee
Fundacion Centro Nac De Investigaciones Oncological Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013903&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57216(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundacion Centro Nac De Investigaciones Oncological Carlos Iii filed Critical Fundacion Centro Nac De Investigaciones Oncological Carlos Iii
Publication of RS57216B1 publication Critical patent/RS57216B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
RS20180576A 2013-03-15 2014-03-14 Hemijske vrste RS57216B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382089 2013-03-15
PCT/GB2014/050825 WO2014140644A1 (en) 2013-03-15 2014-03-14 Chemical entities
EP14716910.6A EP2970332B1 (en) 2013-03-15 2014-03-14 Chemical entities

Publications (1)

Publication Number Publication Date
RS57216B1 true RS57216B1 (sr) 2018-07-31

Family

ID=48013903

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180576A RS57216B1 (sr) 2013-03-15 2014-03-14 Hemijske vrste

Country Status (32)

Country Link
US (1) US9453031B2 (sr)
EP (1) EP2970332B1 (sr)
JP (1) JP6379115B2 (sr)
KR (1) KR102206318B1 (sr)
CN (1) CN105051047B (sr)
AR (1) AR095443A1 (sr)
AU (1) AU2014229735B2 (sr)
BR (1) BR112015023060B1 (sr)
CA (1) CA2904768C (sr)
CL (1) CL2015002591A1 (sr)
CY (1) CY1120619T1 (sr)
DK (1) DK2970332T3 (sr)
EA (1) EA029771B1 (sr)
ES (1) ES2670674T3 (sr)
HK (1) HK1215021A1 (sr)
HR (1) HRP20180839T1 (sr)
HU (1) HUE037685T2 (sr)
IL (1) IL240708B (sr)
LT (1) LT2970332T (sr)
MX (1) MX368056B (sr)
NO (1) NO2970332T3 (sr)
NZ (1) NZ711038A (sr)
PE (1) PE20152007A1 (sr)
PH (1) PH12015502159B1 (sr)
PL (1) PL2970332T3 (sr)
PT (1) PT2970332T (sr)
RS (1) RS57216B1 (sr)
SG (1) SG11201507555PA (sr)
SI (1) SI2970332T1 (sr)
TW (1) TWI557131B (sr)
UA (1) UA118261C2 (sr)
WO (1) WO2014140644A1 (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
BR122019024759B1 (pt) 2013-01-15 2022-02-08 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
JP2016528298A (ja) 2013-08-23 2016-09-15 インサイト・コーポレイションIncyte Corporation Pimキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016112374A2 (en) * 2015-01-09 2016-07-14 The General Hospital Corporation Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3464295B1 (en) * 2016-05-24 2020-02-05 Merck Patent GmbH Tricyclic heterocylic derivatives
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7290651B2 (ja) 2018-02-07 2023-06-13 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Atr阻害剤及びその応用
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN113004303A (zh) * 2019-12-18 2021-06-22 江苏恒瑞医药股份有限公司 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
WO2021143821A1 (zh) * 2020-01-17 2021-07-22 江苏恒瑞医药股份有限公司 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
AU2021360636A1 (en) 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
CN115466258A (zh) * 2021-06-11 2022-12-13 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
CN115286645A (zh) * 2022-08-16 2022-11-04 南京雷正医药科技有限公司 三环杂环衍生物及其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
AU3427093A (en) * 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1154774B1 (en) 1999-02-10 2005-06-22 AstraZeneca AB Quinazoline derivatives as angiogenesis inhibitors
SK287401B6 (sk) 1999-11-05 2010-09-07 Astrazeneca Ab Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
NZ520640A (en) 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
CA2667960A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Imidazopyridazines as pi3k lipid kinase inhibitors
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
BR112012003955A2 (pt) * 2009-08-20 2017-09-26 Karus Therapeutics Ltd compostos heterocíclicos tricíclicos como inibidores da fosfoinositídeos 3-quinase
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
AU2011270807A1 (en) * 2010-06-23 2013-01-31 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase
UA109688C2 (xx) * 2010-12-16 2015-09-25 Трициклічні інгібітори pі3k та їх застосування

Also Published As

Publication number Publication date
ES2670674T3 (es) 2018-05-31
CY1120619T1 (el) 2019-12-11
CN105051047B (zh) 2017-12-15
TWI557131B (zh) 2016-11-11
EA029771B1 (ru) 2018-05-31
MX368056B (es) 2019-09-18
CA2904768A1 (en) 2014-09-18
KR102206318B1 (ko) 2021-01-25
JP2016510803A (ja) 2016-04-11
JP6379115B2 (ja) 2018-08-22
EP2970332A1 (en) 2016-01-20
PE20152007A1 (es) 2016-02-04
MX2015011549A (es) 2016-05-31
SG11201507555PA (en) 2015-10-29
UA118261C2 (uk) 2018-12-26
SI2970332T1 (en) 2018-06-29
CN105051047A (zh) 2015-11-11
PH12015502159A1 (en) 2016-01-25
KR20150129741A (ko) 2015-11-20
WO2014140644A1 (en) 2014-09-18
US9453031B2 (en) 2016-09-27
HK1215021A1 (zh) 2016-08-12
BR112015023060A2 (pt) 2017-07-18
DK2970332T3 (en) 2018-05-22
NO2970332T3 (sr) 2018-07-28
IL240708B (en) 2019-08-29
PH12015502159B1 (en) 2016-01-25
NZ711038A (en) 2020-02-28
TW201446772A (zh) 2014-12-16
CA2904768C (en) 2021-07-27
HUE037685T2 (hu) 2018-09-28
HRP20180839T1 (hr) 2018-06-29
US20160024112A1 (en) 2016-01-28
AR095443A1 (es) 2015-10-14
IL240708A0 (en) 2015-10-29
EP2970332B1 (en) 2018-02-28
PL2970332T3 (pl) 2018-08-31
PT2970332T (pt) 2018-05-25
BR112015023060B1 (pt) 2022-07-05
CL2015002591A1 (es) 2016-02-05
AU2014229735B2 (en) 2018-08-09
LT2970332T (lt) 2018-06-11
AU2014229735A1 (en) 2015-09-03
EA201591781A1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
HRP20180839T1 (hr) Kemijske vrste
HK1222859A1 (zh) 化合物
AU355447S (en) Case
AU354443S (en) Case
AU354395S (en) Case
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
GB201304245D0 (en) Chemical compounds
HK1214592A1 (zh) 化合物
GB201316824D0 (en) New Chemical Entities
HK1215049A1 (zh) 化學交聯劑
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201316823D0 (en) New Chemical Entities
EP3010923A4 (en) PYRROLOCHINAZOLINVERBINDUNGEN
EP2948457A4 (en) COMPOUNDS
GB201322733D0 (en) Chemical compounds
GB201306794D0 (en) Compounds
GB201313885D0 (en) Chemical Compounds
GB201306881D0 (en) Chemical compounds
GB201317911D0 (en) E e e
GB201304305D0 (en) E C Trackograph
GB201307093D0 (en) Compounds
GB201304694D0 (en) Compounds
GB201303482D0 (en) Compounds
GB201303483D0 (en) Compounds